Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific ...

Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful against obesity.

With roughly two in five U.S. adults affected by obesity, GLP-1 drugs have emerged as a promising solution — but their steep price remains a significant hurdle. For instance, GLP-1 drugs have a list ...

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use ...

Patients with obesity sometimes have leptin resistance, and the "full" feeling does not get through to the brain. The new ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad ...

As obesity medicine continues to evolve, integrating sleep health into obesity treatment plans is essential.Poor sleep ...

Acetazolamide plus atomoxetine improved nocturnal CO2 and oxygenation in OHS. Find out more about this proof-of-concept trial.

A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent ...

Rhythm Pharmaceuticals said its Phase 3 trial for setmelanotide for patients with rare, genetically-driven obesities did not meet its primary endpoints.

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...